| | |
| First-in-Human Study of GPRC5D-Targeted CAR T-cell Therapy CT071 with an Accelerated Manufacturing Process for the Treatment of Relapsed/Refractory Multiple Myeloma | |
| Long Term Follow-Up of Zevor-Cel in Patients with Relapsed/Refractory Multiple Myeloma | |
| CAR-TscmCells as anEffective ImmuneTreatment to Multiple Myeloma Patients | |
| CAC-MM-001: Anti-BCMACAR-T Therapy Followed by Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities | Yuntong Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Real-World Outcomes of Equecabtagene Autoleucel, the First Fully Human BCMA-Targeted CAR-T Therapy, in 150 Patients with Multiple Myeloma (MM): A Multicenter Experience from China | |
| Kinetic Characteristics of T Cells in CAR-T Therapy for Multiple Myeloma: A Real-World Analysis | |
| Efficacy and Safety of CAR-T Therapy in CNS-MM | |
| CART–ASCT–CART2 Sandwich Regimen as Frontline Therapy: A Phase II Trial in Patients with Primary Plasma Cell Leukemia | Jingyu Xu，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| BCMACAR T-Cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001) | Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Impact of Frailty Tools on Outcomes in Myeloma: MRP and Simplified Index Predict Survival but Differ in Infection Risk Stratification | |
| A Comparison of Chemo-free Strategy with Plerixafor Plus G-CSF Versus High-Dose Cyclophosphamide Plus G-CSF as First-line PBSC Mobilization in Multiple Myeloma Patients: A Chinese Explorative Study | Xiaoyan Han，浙江大学医学院附属第一医院 |
| Denosumab-Related Osteonecrosis of the Jaw in Patients with Multiple Myeloma: AChinese Single Center Retrospective Cohort Study | |
| Factors Influencing the Outcome of Salvage Second Autologous Stem Cell Transplant in Relapsed Multiple Myeloma | |
| Predicting Early Mortality Risk in Newly Diagnosed
Multiple Myeloma Patients | |
| Incidence and Risk Factors of Thromboembolic Events in Chinese Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study | |
| Dialysis-Dependence is Associated with Poor Prognosis in Multiple Myeloma: a Multicenter Retrospective Cohort Study | Chenyun Wang，浙江大学医学院附属第一医院 |
| Serum Cholesterol Levels Demonstrate Dynamic Changes Following Autologous Hematopoietic StemCell Transplantation in Patients with Multiple Myeloma | |
| Quantitative CD38 Expression and Clinical Response to Anti-CD38 Therapy in Multiple Myeloma: A Retrospective Cohort Analysis | Jianlin Hu，华中科技大学同济医学院附属同济医院 |
| Circulating Plasma Cells as an Independent Prognostic Marker in Newly Diagnosed Multiple Myeloma: Clinical Correlation and Immunophenotypic Insights | Yating Li，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Verification and Optimization of VTE Risk Stratification System for Multiple Myeloma in China Based on Review Cohort | |
| Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis | Yuntong Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Identification of a CAR–Derived Clone by NGS Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma | Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Performance and Additional Benefits of Matrix Assisted Laser Desorption/Ionization-Time-of Flight Mass Spectrometry in M-Protein Detection in Plasma Cell Disorders | Mengmeng Dong，浙江大学医学院附属第一医院 |
| Delayed and Sustained Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma | Jieqiong Zhou，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Dynamic Changes in Cytogenetic Abnormalities Detected by Serial FISH Predict MRD Status and Outcomes in Multiple Myeloma | Jieqiong Zhou，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Potential Roles of YBX1-MIF Axis in Promoting Bone Marrow Inflammation and Multiple Myeloma Progression | Mengping Chen，上海交通大学医学院附属仁济医院 |
| Bortezomib, Lenalidomide, and Dexamethasone Reverses the Inferior Prognostic Effect of KRAS Mutation in Patients with Newly-Diagnosed Multiple Myeloma | |
| Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma | Jian Cui，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma | Chenxing Du，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| MYC Copy Number Variation Detected by FISH Indicates a Similarly Poor Prognosis to MYC Rearrangement in Newly Diagnosed Multiple Myeloma | Chenxing Du，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Imbalance of Glycine Metabolism Contributes to Osteolysis in Multiple Myeloma | |
| Role and Mechanism of Multiple Myeloma Cells in Regulating Macrophage Polarization and the Antitumor Effect via ENO1 | |
| Targeting PIM-2 and PARP1 Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells Through NKG2D Binding | |
| Targeting Lactate Metabolism in Multiple Myeloma to Enhance CAR-T Cells Antitumor Function | |
| LILRB4 Drives Myeloid Immunosuppressive Microenvironment in Multiple Myeloma and Facilitates the Inferior Outcome of Patients | Lanting Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Dual Roles of IRE1α Inhibition in Reversing Mitochondrial ROS-Induced CD8+ T Cell Senescence and Exerting Direct Anti-Tumor Effects in Multiple Myeloma | |
| Insights into Ubiquitination-Associated Genes in Multiple Myeloma: A Multi-Omics Mendelian Randomization Study | |
| Macrophages Promote Aberrant DNA Repair in
Multiple Myeloma Via the CXCL5/CXCR2 Axis | Mengmeng Dong，浙江大学医学院附属第一医院 |
| Crosstalk Between m6A and H3K27ac via the YTHDC1-EP300 Feedback Loop Promotes Myelomagenesis | |
| NAMPT in Myeloma-Associated Macrophages Drives Drug Resistance through Mitochondrial Metabolic Reprogramming and Immune Evasion via the SIRT1/STAT3/SPP1 Axis | Shunnan Yao，浙江大学医学院附属第一医院 |
| NEDD4-1-Mediated Ubiquitination of CCR7 Reprograms Macrophage Function and Enhances theraputic Sensitivity in Multiple Myeloma | |
| The m5C-Binding Protein YB-1 Modulates Proteasome Inhibitors Resistance in Multiple Myeloma Via Epigenetic Modification | |
| LILRB4 Drives Daratumumab Resistance in Multiple Myeloma via STAT3/PIM1 Activation and Lipid Metabolic Reprogramming of the Immune Microenvironment | Xiaoyu Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Enhanced Expression of TAGLN2 Predicts Negative
Prognosis in Multiple Myeloma | Mengping Chen，上海交通大学医学院附属仁济医院 |
| Enhancing Immunotherapy through Metabolic
Modulation in Humanized Multiple Myeloma Mice | |
| Role and Mechanism of Pim-2 Kinase Inhibitors induced Immunogenic Cell Death in Multiple Myeloma | |
| STAT3Inhibitors Inducing DNA DamageinMultiple Myeloma Cells and Enhancing the Anti-Tumor Effects of NK Cells | |
| LILRB4 Protects Multiple Myeloma Cells from
Ferroptosis to Promote MM Progression | Yijie Wang，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| AKR1B1/NAT10 Mediate IL4I1 ac4C Modification to Regulate Tryptophan Metabolism and Promote Multiple Myeloma Proliferation | |
| RNF5-DNAJA1 Axis Dictates Selinexor Sensitivity of Multiple Myeloma | |
| Carfilzomib, Pomalidomide, Dexamethasone ± Daratumumab Delivers Survival Benefit Regardless of Cytogenetic Risk in Early Relapsed Myeloma Patients-A Multi-Center, Prospective Real World Study in China | |
| Inhibition of DNA Damage Response Factor DNA PKcs-Mediated H2AX Phosphorylation Enhances Selinexor-Induced Anti-Multiple Myeloma Effects | Jinna Zhang，浙江大学医学院附属第一医院 |
| A Multi-Step Virtual Screening Framework Identifies Novel GPRC5D Inhibitors for Multiple Myeloma Therapy | |
| Prognostic Determinants of Overall Survival in POEMS Syndrome: A 7-Year Single-Center Retrospective Analysis | Yuhan Bao，华中科技大学同济医学院附属同济医院 |
| Clinical Study on the Efficacy and Safety of Aponermin Combined with Dexamethasone Based Regimen in Multidrug-Resistant Multiple Myeloma | |
| The Study of Serum VEGF Expression in Different Types of Plasma Cell Diseases | |
| Analysis of Clinical Characteristics and Prognostic Factors in Patients with Primary Plasma Cell Leukemia | |
| Profound Decrease of dFLC After One Cycle Predicts Superior Outcome in Patients with AL Amyloidosis Treated with Daratumumab and Bortezomib-Based Regimens | |
| Efficacy and Safety of Daratumumab-Based Regimens in Light Chain Amyloidosis: A Retrospective Single-Center Study | Xinran Wang，华中科技大学同济医学院附属同济医院 |
| Integrative Clinical, Transcriptomic, and Immunohistochemical Characterization of Light Chain Amyloidosis in Bone Marrow and Cardiac Tissue | Chao-Hung Wei，台湾大学医学院附设医院 |
| Efficacy and Safety of Daratumumab, Lenalidomide, and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: A Single-Center Real-World Study in China | |
| Steady-State Hematopoietic Cell Mobilization for Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy Versus IMiD-Based Induction Therapy: A Real- World Experience | |
| HSPA9 Contributes to Tumor Progression and Ferroptosis Resistance by Enhancing Usp14 Driven xCT Deubiquitination in Multiple Myeloma | |
| Impact of CD34+ Cell Infusion Dose on Immune reconstitution and Survival in Multiple Myeloma after Autologous Stem Cell Transplantation | |
| D-VRd-based Dynamic Frailty-Tailored Therapy (DynaFiT-v2) in Elderly Patients with Newly Diagnosed Multiple Myeloma: a Prospective Study | |
| Interim Analysis of DARAVRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT as First Line in China | |
| Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed Multiple Myeloma: Outcome and Safety Profile from a Multi-Center Real-World Experience | |
| Dara-VCd in Newly Diagnosed Multiple Myeloma with Severe Renal Impairment: A Prospective Multicenter Single-Arm Study | |
| Early Identification of Patients with Multiple Myeloma Progressing within a Short-Term following Tandem Transplantation | |
| Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on the Treatment of Multiple Myeloma: ASingle-Center Clinical Analysis on PFS | Hailong Yuan，新疆医科大学第一附属医院 |
| Efficacy and Safety of Ixazomib-Based Maintenance Therapy after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients: A Retrospective Analysis | Hailong Yuan，新疆医科大学第一附属医院 |
| Efficacy and Safety of Biweekly/Weekly Ixazomib Dexamethasone Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma: A Multi-Center Study | Xiaoyan Han，浙江大学医学院附属第一医院 |
| Selinexor Combined Bortezomib, Lenalidomide, andDexamethasonefor NewlyDiagnosedMultiple Myeloma with High-Risk Cytogenetics Abnormalities: A Single-Arm, Multi-Center, Observational Clinical Study | |
| Efficacy and Safety of a China-Developed BCMA Targeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-World Multicenter Experience | |
| Exploration of Efficacy for Frailty-Adjusted Dose Reduced Pcd Regimen in Relapsed/Refractory Multiple Myeloma | |
| Clinical Features and Management of GPRC5D related AE in Chinese Relapsed/Refractory Multiple Myeloma Patients Treated with Talquetamab: MonumenTAL-1 China Cohort Experience | 安刚，中国医学科学院血液病医院（中国医学科学院血液学研究所） |
| Real-World Treatment Patterns, Effectiveness, and Safety of Daratumumab-based Regimens in Chinese Patients with Multiple Myeloma: Final Analysis of the MMY4032 Study | |
| BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma | |
| Case Report: BCMA-targeting CAR T-cell Therapy Induces Complete and Durable Remission in Relapsed Extramedullary Plasmablastic Multiple Myeloma | |
| Efficacy and Safety of Low-frequency Daratumumab in Systemic Light-chain Amyloidosis | |
| Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma | |
| Single-Cell Sequencing Reveals Transcriptional and Metabolic Divergence of Bone-Involved Multiple Myeloma | |
| Nutritional Status Indices on the Prognosis of Patients with Relapsed and Refractory Multiple Myeloma Treated with CAR-T Cell Immunotherapy | |
